Needham analyst James Ricchiuti maintains II-VI (NASDAQ:IIVI) with a Buy and lowers the price target from $84 to $70.
Needham Maintains Buy on II-VI, Lowers Price Target to $70
Needham analyst James Ricchiuti maintains II-VI (NASDAQ:IIVI) with a Buy and lowers the price target from $84 to $70.
Related Posts
FibroBiologics Presents Data From Dermal Fibroblast Spheroid-Based Treatment Of Chronic Wounds In A Diabetes Mouse Model At Advanced Wound Care Summit USA
FibroBiologics, Inc., (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases using
Susquehanna Maintains Neutral on GATX, Raises Price Target to $115
Susquehanna analyst Bascome Majors maintains GATX (NYSE:GATX) with a Neutral and raises the price target from $110 to $115.
Analyst Expectations For Corteva’s Future
Providing a diverse range of perspectives from bullish to bearish, 13 analysts have published ratings on Corteva (NYSE:CTVA)…